第一或通讯作者 

1.Jiang HB, Li L, Zhu D, Zhou XY, Yu YS*, Zhou Q, Sun LM. A Review of Nanotechnology for Treating Dysfunctional Placenta. Frontiers in Bioengineering and Biotechnology. 2022, 10:845779. 

2.Chen K, Liu MX, Wang F, Hu YP, Liu P, Li C, Du QQ, Yu YS*, Xiao XF, Feng Q. Highly Transparent, Self-Healing, and Self-Adhesive Double Network Hydrogel for Wearable Sensors. Frontiers in Bioengineering and Biotechnology. 2022, 10:846401. 

3. Chen K, Hu YP, Wang F, Liu MX, Liu P, Li C, Yu YS*, Xiao XF, Feng Q. Ultra-stretchable, adhesive, and self-healing MXene/polyampholytes hydrogel as flexible and wearable epidermal sensors. COLLOID SURFACE A. 2022,645:128897. 

4. Zhang KY, Wan Z, Jiang HB, Xiao XF, Feng Q, Meng YC, Yu YS*. Dimer targeting peptide mediated precise and controllable drug delivery by upconversion nanocarriers for breast cancer therapy. Materials and Design, 2021,203:109597. 

5. Hou JJ, Tan YY, Su C, Wang T, Gao Z, Song D, Zhao J, Liao Y, Liu X, Jiang Y, Feng Q, Wan Z, Yu YS*. Inhibition of FAK enhances 5-FU chemosensitivity to gastric carcinoma via the MAPK-ERK and p53 signaling pathways. Computational and Structural Biotechnology Journal, 2020,18:125-136.  

6.Huang Y, Feng Q, Jiang H, Zhou W, Chen J, Gao J, Wang K, Wan X, Yu YS*. Mimicking the Endometrial Cancer Tumor Microenvironment to Reprogram Tumor-Associated Macrophages in Disintegrable Supramolecular Gelatin Hydrogel. International Journal of Nanomedicine. 2020,15:4625-4637.  

7.Jiang HB, Li L, Zhang J, Wan Z, Wang Y, Hou JJ, Yu YS*. MiR-101-3p and Syn-Cal14.1a Synergy in Suppressing EZH2-Induced Progression of Breast Cancer. OncoTargets and Therapy, 2020, 13:9599-9609. 

8. Wan Z, Jiang HB, Li L, Zhu S, Hou JJ, Yu YS*. Carcinogenic roles and therapeutic effects of EZH2 in gynecological cancers. Bioorganic Medicinal Chemistry. 2020,28(7):115379. 

9.Yu YS, Li SD, Wang K, Wan XP. A PDZ protein MDA-9/Syntenin: as a target for cancer therapy. Computational and Structural Biotechnology Journal, 2019, 17,136-141. 

10. Liu JH, Qu JL, Zhou WD, Huang XJ, Xia J, Yu YS*. Syntenin-targeted peptide blocker inhibits progression of cancer cells. European Journal of Medicinal Chemistry, 2018,154:354-366. 

11.Yu YS, Nie YY, Feng Q, et al.,Targeted covalent inhibition of Grb2？Sos1 interaction through proximity-induced conjugation in breast cancer cells. Molecular Pharmaceutics, 2017,14:1548-1557.  

12.Yu YS, Xia J. Affinity-guided protein conjugation：the trilogy of covalent protein labeling, assembly and inhibition. Science China-Chemistry, 2016, 07:853-861. 

13.Yu YS, Liu M, Ng TT, et al., PDZ-reactive peptide activates Ephrin-B reverse signaling and inhibits neuronal chemotaxis. ACS Chemical Biology, 2016, 11:149-158.  

14.Yu YS, Wang JP, Liu JH, Ling DS, Xia J. Functional assembly of protein fragments induced by spatial confinement. PLoS One, 2015, 10:e0122101. 

15.Gao J, Yu YS#, Zhang YY, et al., EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma, Biomaterials, 2012, 33: 270-82.  

16.Gao J, Chen HW, Yu YS#, et al., Inhibition of hepatocellular carcinoma growth using immunoliposomes for codelivery of Adriamycin and ribonucleotide reductase M2 siRNA. Biomaterials, 2013, 34:10084-98. 

17.Kang W, Ding CF, Zheng DN, Ma X, Yi L, Tong XY, Wu C, Xue C, Yu YS*, Zhou Q. Nanobody conjugates for targeted cancer therapy and imaging. Technology in Cancer Research & Treatment, 2021, DOI: 10.1177/15330338211010117.  

18.Yang YY, Feng Q, Ding CF, Kang W, Xiao XF, Yu YS*, Zhou Q. Controllable Drug Delivery by Na+/K+ ATPase α1 Targeting Peptide Conjugated DSPE-PEG Nanocarriers for Breast Cancer. Technology in Cancer Research & Treatment, 2021, https://doi.org/10.1177/15330338211027898.